Aethlon Medical INC 8-K filings

Aethlon Medical, Inc. announced a 1-for-5 reverse stock split to manage dilution and maintain Nasdaq compliance, effective July 31, 2026.

Aethlon Medical has filed an amendment to its prospectus supplement, allowing for the sale of up to $542,716 in common stock under an existing at-the-market agreement.

Aethlon Medical, Inc. announced that all previously outstanding pre-funded warrants have been exercised, resulting in 1,569,110 shares of common stock outstanding.

Aethlon Medical, Inc. stockholders approved a significant increase in authorized common stock and expanded its equity incentive plan at the Annual Meeting on February 19, 2026.

Aethlon Medical, Inc. announced its fiscal third quarter 2026 financial results, highlighting continued clinical and research program advancements alongside year-to-date cost efficiencies.

Aethlon Medical, Inc. amended agreements with an institutional investor, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable.

Aethlon Medical, Inc. announced a private placement and warrant inducement deal, raising approximately $3.3 million in gross proceeds to fund operations and clinical trials.

Aethlon Medical reported a 48% reduction in operating expenses for fiscal Q2 2025 while progressing its Australian oncology trial and Long COVID research.

Aethlon Medical, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Aethlon Medical, Inc. received a Nasdaq delisting notice due to its common stock trading below the $1.00 minimum bid price requirement, prompting a hearing request and a 1-for-10 reverse stock split.

Aethlon Medical, Inc. will implement a 1-for-10 reverse stock split to manage dilution and maintain Nasdaq listing compliance, effective October 16, 2025.

Aethlon Medical, Inc. announced 7,373,156 outstanding shares as of September 12, 2025, following a recent best-efforts public offering.

Aethlon Medical, Inc. announced the pricing and closing of a public offering, raising approximately $3.9 million in net proceeds for general corporate purposes.

Aethlon Medical, Inc. provided an updated corporate presentation highlighting clinical progress of its Hemopurifier device in oncology and infectious diseases, alongside its financial position.

Aethlon Medical announced its fiscal first quarter 2025 financial results, reporting a reduced net loss and significant progress in its Australian cancer trial for the Hemopurifier.

Aethlon Medical announced its fiscal fourth-quarter 2025 financial results, highlighting progress in its Hemopurifier cancer trials in Australia and India, significant reductions in operating expenses, and advancements in its Long COVID research.

Aethlon Medical, Inc. has announced a 1-for-8 reverse stock split of its common stock, effective June 6, 2025, with split-adjusted trading to commence on Nasdaq on June 9, 2025.

Aethlon Medical's stockholders approved a reverse stock split and the issuance of shares upon exercise of inducement warrants at a special meeting held on May 13, 2025.

Aethlon Medical secures $2.3 million through warrant inducement agreement, issuing new warrants and adjusting exercise prices.

Aethlon Medical announces financial results for Q3 2024, highlighting progress in oncology trials and cost-cutting measures.

Aethlon Medical has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to June 23, 2025.

Aethlon Medical reports that its Hemopurifier device demonstrated 99% removal of H5N1 virus in a laboratory setting within 6 hours, amidst growing concerns about the spread of Bird Flu.

Aethlon Medical announced its fiscal second quarter results, highlighted by the enrollment of the first two patients in its cancer trial and cost-cutting measures.

Aethlon Medical has announced the enrollment of the first patient in its Australian clinical trial for the Hemopurifier device, targeting solid tumors resistant to anti-PD-1 therapies.

Aethlon Medical has appointed James B. Frakes as its permanent CEO, effective October 3, 2024, while also announcing the departure of Chief Operating Officer Guy F. Cipriani.

Aethlon Medical, Inc. stockholders approved an amendment to the company's 2020 Equity Incentive Plan, increasing the number of shares authorized for issuance by 3,000,000.

Aethlon Medical has received ethics approval to begin a clinical trial in India for its Hemopurifier device in cancer patients with solid tumors not responding to anti-PD-1 antibodies.

Aethlon Medical announced a 24% reduction in operating expenses for the fiscal first quarter ended June 30, 2024, and provided updates on its Hemopurifier clinical trials.

Aethlon Medical has secured a second ethics committee approval to proceed with a clinical trial of its Hemopurifier device in cancer patients at Pindara Private Hospital in Australia.

Aethlon Medical, Inc. has dismissed Baker Tilly US, LLP and engaged Haskell & White LLP as its new independent registered public accounting firm, effective July 1, 2024.